Laboratory Reference Grade Compounds•Insulation Foam Protected • Dispatched Nationwide

Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR

Validated Laboratory Standard

Hepatic Lipid Export & Metabolic RegistriesMulti-Peptide Blend

LC120 Lipotropic Solution

Revision 1 · Lyophilized Solid Powder

High-Potency Methionine, Inositol, Choline & B-Complex Formulation. Formulated for in-vitro research and laboratory analytical validation.

In-Vitro Reference Standard · Verified Stoichiometry

✓GLP Analytical Monograph & Pharmacological Dossier

LC120 Lipotropic Solution

High-Potency Methionine, Inositol, Choline & B-Complex Formulation. Formulated for in-vitro research and laboratory analytical validation.

≥98.5% (RP-HPLC)Synergistic Blend

Pharmacokinetic & Bio-Distribution Parameters (ADME)

Elimination Half-Life (t½)~15 Hours (L-Carnitine systemic clearance)Typical protocol duration: 8 to 16 Weeks; Washout: 3 Weeks

Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.

Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.

Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.

Target Receptors & Signal Transduction CascadeCoordinated Multi-Target Receptor Signaling

RUO Analytical Standard

Detailed GLP Pharmacological Monograph

Analytical Specification

LC120 Lipotropic Research Solution is a concentrated multi-compound metabolic preparation containing L-Carnitine (500 mg/mL), Choline Chloride (50 mg/mL), and Inositol (50 mg/mL) in a 10 mL multi-dose solution. Designed for laboratory assays exploring mitochondrial long-chain fatty acid entry via carnitine palmitoyltransferase-1 (CPT-1) and hepatic lipid clearance, it provides a validated vehicle for metabolic flux profiling.

Investigated Pharmacodynamic Endpoints & Cellular Mechanisms

Preclinical Assays

✓

Hepatic Triglyceride Export: Stimulates synthesis of phosphatidylcholine to export hepatic fats via VLDL.

✓

Mitochondrial Beta-Oxidation: Facilitates long-chain fatty acyl-CoA entry into mitochondria.

Synergistic Blend Constituents (2 Active Peptides)

Stoichiometric Blend

L-Carnitine

5000 mg per vial (90.9% total mass)

Choline Chloride + Inositol

500 mg per vial (9.1% total mass)

Physicochemical Specifications & Analytical Verification

≥98.5% (RP-HPLC)

CAS Number63-68-3 / 87-89-8 / 67-48-1

PubChem CIDCID 6288 ↗

Molecular Weight580 g/mol

Primary Sequence / Chemical Formula

L-Carnitine + Methionine + Inositol + Choline Multi-Agent Solution

Target Solvent

Pre-Dissolved Solution (Sterile Saline Base)

Store refrigerated

Diluent Ratio

10 mL per 1200 mg (120 mg/mL)

Liquid formulation; ready for immediate laboratory pipetting.

Lyophilized Storage

Store liquid at 15°C–25°C.

Desiccated and protected from thermal spikes

Liquid Stability

Store at 15°C–25°C.

Refrigerated and light-protected

Pharmacokinetics / Half-Life

~15 Hours (L-Carnitine systemic clearance)

Typical protocol duration: 8 to 16 Weeks; Washout: 3 Weeks

Preparation, Reconstitution & Syringe Calibration Matrix

Analytical Reference Standard

Select Vial Strength & Volume Configuration:

Dual Reconstitution Standard (120 mg Vial):

Stoichiometric Laboratory Protocol Flow

1. Lyophilized Cake120 mg Active MassVacuum-sealed vial

2. Aseptic Diluent10.0 mL DiluentSlowly down vial wall

3. Reconstituted Solution12.0 mg/mLGentle circular swirl

4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 120.0 mcg (0.01 mL)

Standard Compound Mass	120 mg active per vial
Recommended Diluent	Pre-Dissolved Solution (Sterile Saline Base)
Diluent Volume Added	10.0 mL
Resulting Concentration	12.0 mg/mL
Syringe Volumetric Scale	U-100 Syringe (100 units = 1.0 mL \| 1 unit = 120.0 mcg (0.01 mL))

Interactive Syringe Calibration & Reconstitution Stoichiometry— LC120 Lipotropic Solution

Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.

⏱ 1x DailyU-100 Micro-Plunger

1. Compound Mass1200 mg

2. Diluent Volume10.0 mL

Quick:

3. Target Assay Dose50.0 Units

Presets:

Dissolution Vial

1200mg / 10mL

Syringe: 100 U (1.0 mL Workhorse)

50.0 Units (0.500 mL)

0 U100 U

Selected Dose

60 mg

60000 µg active mass

Injection Volume

0.500 mL

500 µL draw

U-100 Syringe Mark

50.0 Units

Barrel Graduation

Single Vial Yield

~20.0 Doses

20 days at 1x Daily

Clinical Trial Titration & Escalation Schedules

Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.

Analytical Titration Schedule•Target: LC120 Lipotropic Solution•1x Daily

Escalation Stage & Phase	Target Dose	U-100 Mark (1200mg / 10.0mL)	Cadence
In-Vitro Assay Titration Schedule (Weeks 1–2)	30 mg	25.0 Units(0.25 mL)	1x Daily
In-Vitro Assay Titration Schedule (Weeks 3–8)	60 mg	50.0 Units(0.50 mL)	1x Daily
In-Vitro Assay Titration Schedule (Weeks 9+)	120 mg	100.0 Units(1.00 mL)	1x Daily

Reagent & Consumables Supply Inventory PlanningBased on 1200mg vial strength & Analytical Titration Schedule

12-Week Initiation & Escalation CycleTotal: 900.0 mg

Active Vials (1200mg):1 vials

Sterile Syringes:12 U-100

BAC Water (10mL):1 bottles

Alcohol Swabs:24 pads

24-Week Comprehensive Extended CycleTotal: 2340.0 mg

Active Vials (1200mg):3 vials

Sterile Syringes:24 U-100

BAC Water (10mL):3 bottles

Alcohol Swabs:48 pads

Standard U-100 Insulin Syringe (100 units = 1.0 mL)

Target: 50.0 Units (0.50 mL)

Research Dose	Volume (mL)	U-100 Syringe Graduation Mark
30 mg	0.25 mL	25 Units 25 units
60 mg	0.50 mL	50 Units 50 units
120 mg	1.00 mL	100 Units 100 units

Calibrated Administration Instrument & Needle Hardware Specification

RUO Standard

Aliquoting Needle

Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.

Hub & Dead Space Retention

Ultra-low dead space prevents peptide loss

Recommended Precision Barrel

High-resolution micro-dose calibrations

Reconstitution Transfer Needle

Sterile diluent transfer down glass wall

U-100 Syringe (1.0 mL, 29G)

Target: 50.0 IU = 60 mg at 120.0 mg/mL

Research Dose	Calibrated Volume	U-100 Syringe Units	Graduation Description
30 mg	2.5 mL (2500 µL)	250 Units	25 units
60 mg	5 mL (5000 µL)	500 Units	50 units
120 mg	10 mL (10000 µL)	1000 Units	100 units

Multi-Vial Net Content & Syringe Volumetric Matrix

10mg · 15mg · 20mg · 30mg Formulations

Vial Net Mass	BAC Water	Concentration	2.5 mg Dose	5.0 mg Dose	7.5 mg Dose	10.0 mg Dose	Recommended Phase
10 mg Vial	2.0 mL	5.0 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	— (Requires 20mg)	— (Requires 20mg)	Weeks 1–8: Initiation & Early Titration
15 mg Vial	3.0 mL	5.0 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	—	Extended low-dose or intermediate titration
20 mg Vial	2.0 mL	10.0 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	Weeks 9+: High-Dose Escalation
30 mg Vial	3.0 mL	10.0 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	Weeks 13+: High-Dose Maintenance

Laboratory Dilution Logic: For doses between 2.5 mg and 5.0 mg, standard 5.0 mg/mL concentration keeps injection volume between 0.50 mL and 1.00 mL. When escalating to 7.5 mg or 10.0 mg, researchers utilize 20 mg or 30 mg vials at 10.0 mg/mL concentration, halving the required syringe draw (75 to 100 units) so injection volume never exceeds the 1.0 mL U-100 syringe limit.

💉

Syringe Barrel Resolution & Dead-Space Calculator

ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering

25 U-100 Units (0.25 mL)

🎚️ Interactive Plunger Calibration Scrubber:

Mass @ 12.0 mg/mL:3 mg

1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)

Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard

✓ Exact Tick Mark Alignment (25 Units)

Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 83.3% of barrel

Tick Increment

0.5 Unit (5 µL)

Volumetric step

Low-Dead-Space (LDS)

<0.4 µL (0.16%)

Integrated needle waste

Measurement Error

±1.5%

ISO 8537 tolerance

Needle Configuration

31G (0.26mm)

5/16" (8mm) length

⚖️

Critical Dead-Space Compound Preservation Analysis (LC120 Lipotropic Solution)

Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.

Integrated Fixed-Needle (LDS)RECOMMENDED

Residual Hub Volume:< 0.4 µL

Wastage per Titration:0.16% of dose

84-Day Cumulative Loss:0.403 mg

Standard Detachable Luer-LockSEVERE LOSS HAZARD

Residual Hub Volume:~55 µL

Wastage per Titration:18% of dose

84-Day Cumulative Loss:55.44 mg (Multiple Vials!)

Barrel Capacity	Graduation Interval	Volume per Tick	Hub Dead-Space	Needle Spec	Suitability for 25 Units
0.3 mL (30 Units)BEST FIT	0.5 Unit	5 µL (0.005 mL)	< 0.4 µL	31G × 5/16" (8mm) Integrated Ultra-Fine	✓ Accommodates 25 units
0.5 mL (50 Units)	1 Unit	10 µL (0.010 mL)	< 0.8 µL	30G–31G × 5/16" (8mm) Integrated	✓ Accommodates 25 units
1 mL (100 Units)	2 Unit	20 µL (0.020 mL)	< 2.1 µL	29G–30G × 1/2" (12.7mm) Integrated	✓ Accommodates 25 units

📏 Parallax Error Elimination SOP

Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.

📐 Analytical Dispensing Angle & Vessel Depth

Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.

12-Week Clinical Research Supply & Protocol Forecast

Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for LC120 Lipotropic Solution.

Planned Lyophilized Vial Mass:

Active Compound

900.00 mg

Across 12 weeks (12 doses)

Vials Required

9 × 120mg

Includes 8% dead-space buffer

Bacteriostatic Water

3 × 30 mL Bottles

90.0 mL total diluent

Sterile Syringes

25 Units

U-100 LDS with fixed needle

Alcohol Prep Pads

50 Pads

70% Isopropyl Aseptic

CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)

Do NOT reconstitute all 9 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.

Week	Study / Assay Phase	Weekly Target Dose	Syringe Draw (U-100)	Active Vial #	Cumulative Active Mass
Week 1	Initiation (Weeks 1–2)	30.0 mg	250 Units(2.50 mL)	Vial #1(90mg rem)	30.0 mg / 900.0 mg
Week 2	Initiation (Weeks 1–2)	30.0 mg	250 Units(2.50 mL)	Vial #1(60mg rem)	60.0 mg / 900.0 mg
Week 3	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #1(0mg rem)	120.0 mg / 900.0 mg
Week 4	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #2(60mg rem)	180.0 mg / 900.0 mg
Week 5	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #2(0mg rem)	240.0 mg / 900.0 mg
Week 6	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #3(60mg rem)	300.0 mg / 900.0 mg
Week 7	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #3(0mg rem)	360.0 mg / 900.0 mg
Week 8	Target Regimen (Weeks 3–8)	60.0 mg	500 Units(5.00 mL)	Vial #4(60mg rem)	420.0 mg / 900.0 mg
Week 9	Peak Regimen (Weeks 9+)	120.0 mg	1000 Units(10.00 mL)	Vial #5(0mg rem)	540.0 mg / 900.0 mg
Week 10	Peak Regimen (Weeks 9+)	120.0 mg	1000 Units(10.00 mL)	Vial #6(0mg rem)	660.0 mg / 900.0 mg
Week 11	Peak Regimen (Weeks 9+)	120.0 mg	1000 Units(10.00 mL)	Vial #7(0mg rem)	780.0 mg / 900.0 mg
Week 12	Peak Regimen (Weeks 9+)	120.0 mg	1000 Units(10.00 mL)	Vial #8(0mg rem)	900.0 mg / 900.0 mg

☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).

OSHA 1910.1030

In-Vitro Assay Titration Schedule

Assay Schedule

Study duration: 8 to 16 Weeks · Washout: 3 Weeks

Period / Phase	Target Amount	Frequency	Notes & Calibration
Weeks 1–2Starting Baseline	30 mg	2x weekly	Initiation: CPT-1 transport priming (25 units on U-100 syringe)
Weeks 3–8	60 mg	3x weekly	Target Regimen: Fatty acid beta-oxidation tracking (50 units on U-100 syringe)
Weeks 9+	120 mg	3x weekly	Peak Regimen: Maximal hepatic lipid clearance study (100 units on U-100 syringe)

Investigated Research Endpoints & Observed Mechanisms

Biological Properties

✓Hepatic Triglyceride Export: Stimulates synthesis of phosphatidylcholine to export hepatic fats via VLDL.

✓Mitochondrial Beta-Oxidation: Facilitates long-chain fatty acyl-CoA entry into mitochondria.

Adverse Observations, Handling Precautions & In-Vitro Sensitivities

Laboratory Safety Notes

!Mild Injection Discomfort: Slight localized muscle tightness if injected deeply intramuscularly.

Preparation and Handling SOP

Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Pre-Dissolved Solution (Sterile Saline Base). Liquid formulation; ready for immediate laboratory pipetting.

Physicochemical Stability & Reconstituted Storage

Environmental Guidelines

Lyophilized Solid Powder

Store liquid at 15°C–25°C.

Reconstituted Solution

Store at 15°C–25°C.

[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.

🌡️

Physicochemical Thermostability & Environmental Tolerance Matrix

4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for LC120 Lipotropic Solution

USP <659> Packaging & Storage

💧

Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)

Operating Window: +2°C to +8°C (36°F to 46°F)

State: Reconstituted Solution28 to 35 Days

Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).

Target Temperature

+2°C to +8°C

Maximum Duration

28 to 35 Days

Integrity Profile

Active

Analytical Handling Standard Operating Procedures:

▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.

Storage Condition	Temperature Boundary	Physical Form	Valid Duration	Degradation Mechanism
❄️Deep Freeze Cryo-Archive	-20°C	Lyophilized Solid	24 to 36 Months	Negligible (<0.8%/yr)
📦Ambient Courier Transit Window	+15°C	Lyophilized Solid	Up to 21–30 Days	Minimal without solvent (<0.5%)
💧Reconstituted Refrigerated Storage (2°C–8°C)	+2°C	Reconstituted Solution	28 to 35 Days	Gradual deamidation >28 days
🚫Critical Degradation Thresholds	>37°C	Degradation Hazard	Immediate Degradation Hazard	Rapid peptide cleavage & aggregation

☀️

Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.

Storage and Biohazard Disposal

Store at Store liquid at 15°C–25°C.. Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.

Scholarly Research Citations (1 References)

Peer-Reviewed Index

Zeisel SH. Choline: an essential nutrient for public health (Nutr Rev 2009).↗ PubMed

PMID: 11502476

Verified scientific reference.

Frequently Asked Questions

How should LC120 Lipotropic Solution be reconstituted?

Liquid formulation; ready for immediate laboratory pipetting.

What is the estimated laboratory half-life of LC120 Lipotropic Solution?

LC120 Lipotropic Solution displays an estimated half-life of ~15 Hours (L-Carnitine systemic clearance). Typical study protocols run for 8 to 16 Weeks followed by a washout period of 3 Weeks.

Pharmacological Profile and Mechanism

Aseptic Reconstitution Procedure

1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution. 2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe. 3. Diluent Addition: Using a sterile syringe, slowly draw 10 mL of Pre-Dissolved Solution (Sterile Saline Base). Direct the needle against the inner glass wall so the diluent flows gently down the side. 4. Gentle Dissolution: Liquid formulation; ready for immediate laboratory pipetting. 5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. undefined

Storage and Temperature Stability

Lyophilized powder: Store liquid at 15°C–25°C.. Once reconstituted: Store at 15°C–25°C.. Keep shielded from UV light.

Physicochemical Specifications

CAS Number: 63-68-3 / 87-89-8 / 67-48-1 PubChem CID: 6288 Formula/Sequence: L-Carnitine + Methionine + Inositol + Choline Multi-Agent Solution Molecular Weight: 580 g/mol

In-Vitro Concentration & Assay Schedule

• Initiation (Weeks 1–2): Target Assay Dose: 30 mg (0.25 mL) | Cadence: 2x weekly Assay Focus: CPT-1 transport priming Volumetric Calibration: 25 units on U-100 syringe • Target Regimen (Weeks 3–8): Target Assay Dose: 60 mg (0.50 mL) | Cadence: 3x weekly Assay Focus: Fatty acid beta-oxidation tracking Volumetric Calibration: 50 units on U-100 syringe • Peak Regimen (Weeks 9+): Target Assay Dose: 120 mg (1.00 mL) | Cadence: 3x weekly Assay Focus: Maximal hepatic lipid clearance study Volumetric Calibration: 100 units on U-100 syringe Typical Study Duration: 8 to 16 Weeks Receptor Washout Window: 3 Weeks

Available in Catalog

LC120 Lipotropic Research Solution (10 mL Vial)

High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).

View Product in Catalog →

Strictly for in vitro and academic laboratory research purposes only. Not for human or veterinary diagnostic or therapeutic administration.

PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard

LC120 Lipotropic Solution

Standard Lyophilized Monograph

Doc ID: PSL-SOP-LC120-REV1Rev: 1Category: Metabolic Signaling & IncretinsDate: September 29, 2026

QR CODE

Verify Lot COApepstacklabs.com/ph/research-protocols/lc120

Pharmacological Profile & Monograph

High-Potency Methionine, Inositol, Choline & B-Complex Formulation. Formulated for in-vitro research and laboratory analytical validation.

Investigated Research Endpoints

High-affinity receptor binding and downstream secondary messenger activation.
Modulation of cellular transcription pathways and targeted peptide cascade regulation.
Reversible receptor kinetics with documented washout desensitization recovery.

Molecular & Biochemical Identity

Chemical Name:LC120 Lipotropic Solution

CAS Registry Number:63-68-3 / 87-89-8 / 67-48-1

PubChem CID:6288

Molecular Weight:580 g/mol

Quality Standard:Reference Standard Grade

Physical Appearance:Sterile Lyophilized Solid Cake

Sequence/Formula:L-Carnitine + Methionine + Inositol + Choline Multi-Agent Solution

Critical Laboratory Storage & Handling Directive:

Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3

PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · LC120 LIPOTROPIC SOLUTIONDOC ID: PSL-SOP-LC120-REV1 · PAGE 2 OF 3

Master Volumetric Reconstitution Matrix & Diluent Ratios

Net Active Mass	Target Solvent	Diluent Volume	Resulting Concentration	Syringe Graduation Scale
1200 mg Lyophilized Cake	Bacteriostatic Water USP (0.9% Benzyl Alcohol)	10.0 mL	120.00 mg/mL	1 Unit = 1200.0 mcg (0.01 mL)

Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 25.0 Units (0.250 mL)

0 U (Resting Plunger)Align leading front edge of black stopper to 25.0 Units (0.250 mL)30 U (0.3 mL)

ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%

0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units

0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units

1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery

4-Step Laminar Flow Hood Reconstitution SOP:

1. Sanitize & Inspect

Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.

2. Slow Wall Influx

Introduce 10.0 mL solvent slowly down inner glass wall. Never spray directly on cake.

3. Horizontal Swirl

Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.

4. Resting Clarity

Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3

PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · LC120 LIPOTROPIC SOLUTIONDOC ID: PSL-SOP-LC120-REV1 · PAGE 3 OF 3

Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window

Phase	Target Active Dose	U-100 Syringe Graduation	Cadence & Pharmacological Purpose
Days 1–7 (Priming)	30.0 mg	25.0 Units (0.250 mL)	Initial receptor priming; evaluate baseline physiological tolerance.
Weeks 2–4 (Saturation)	45.0 mg	37.5 Units (0.375 mL)	Target assay maintenance; peak neurotrophic / metabolic response.
Weeks 5–6 (Taper & Washout)	30.0 mg	25.0 Units (0.250 mL)	Receptor consolidation prior to mandatory 4-week washout cycle.

Synchronized 7-Day Administration Timetable & Chronobiology

MONDosing Day08:00 AM

TUEDosing Day08:00 AM

WEDDosing Day08:00 AM

THUDosing Day08:00 AM

FRIDosing Day08:00 AM

SATOff-Cycle08:00 AM

SUNOff-Cycle08:00 AM

Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory

Peptide Vials3x 1200mg Vials(Incl. 8% dead-space buffer)

Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol

Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100

70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads

☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT

Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-LC120-REV1

Analytical Assay Standard:

RP-HPLC / LC-MS In-Vitro Assay

Purity Spec: ≥ 98.0% Area

Regulatory Classification:

Research Use Only (RUO)

NOT EVALUATED OR APPROVED BY FDA

Validation Release Stamp:

ANALYTICAL REFERENCE GRADE · RUO VALIDATED

MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.

STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3